Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
_256_384.jpg)
The antiviral technology involves the presence of active positive charges on the fabric, as binding sites for viruses and on contact with the fabric, virus cells that are negatively charged are neutralised, leading to the rapid destruction of their glycoprotein layers and the release of non-infectious ribonucleic acid (RNA)
The project is a collaboration between IIT Delhi and AIIMS
The company reports revenue growth of 26% and PAT growth of 21% YoY
The group has a total of 320 ANDA approvals
Substantial reduction in losses
Anti-malaria API facility will be operational in 15-18 months
Subscribe To Our Newsletter & Stay Updated
